Jefferies has reaffirmed its 'Buy' rating for Haleon plc (HLN), setting a price target of p450.00. This continued positive outlook persists despite the unexpected difficulties faced by the company's cold and flu product division in the fourth quarter of 2025. Nonetheless, Haleon's broader portfolio exhibited strong performance, achieving over 4% growth, even as American consumers reduced their stockpiles. The firm acknowledges the impending headwinds from the cold and flu season in the first quarter of 2026 but maintains confidence in Haleon's ability to deliver a 4% like-for-like growth.
Haleon plc, through its global subsidiaries, is actively engaged in the research, development, manufacturing, and distribution of a diverse range of consumer healthcare products. Its operational footprint spans across key regions including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific, highlighting its broad market reach and established presence in the consumer health sector.
The analyst's continued bullish sentiment underscores a belief in the company's long-term value, suggesting that despite short-term market fluctuations, Haleon possesses intrinsic strengths that warrant investment. The company's resilience in diversifying its product offerings and maintaining growth in other segments mitigates the impact of temporary downturns in specific product categories. This strategic diversification positions Haleon to navigate market challenges more effectively and sustain its overall business trajectory.
Despite the anticipated impact of the cold and flu season, the firm emphasizes that an increase in Haleon's underlying growth to 5%, coupled with a 9% expansion in emerging markets, would significantly bolster its valuation. This outlook suggests that strategic market penetration and sustained growth in key areas are crucial for enhancing investor confidence and market capitalization.
In summary, Jefferies' maintained 'Buy' rating for Haleon plc reflects a calculated optimism about the company's future. While acknowledging immediate challenges in specific product categories, the analysis highlights the company's robust overall growth, strategic market positioning, and the potential for enhanced valuation through sustained growth and market expansion. This perspective provides investors with a clear rationale for considering Haleon as a valuable long-term investment in the consumer healthcare domain.
